DurvalumabPublished on: 17 Apr 2018
ECHO-203: IDO1 and PD-L1 inhibition in advanced solid tumors
An immunotherapy treatment combining the IDO1 inhibitor epacadostat and the PD-L1 inhibitor durvalumab was found to be safe in patients with advanced solid tumors.
